Consensus Pfizer Cinnober Boat

Stocks

PFZ

US7170811035

Pharmaceuticals

Real-time Estimate Tradegate 06:28:07 2026-10-05 EDT			5-day change	1st Jan Change
24.84 ^EUR	0.00%		0.00%	-

10-02	AbbVie joins US government pilot to test drug discount rebates	RE
10-02	Pfizer Inc. Presents Results From Two Phase 3 Trials Evaluating LITFULO As Once-Daily Oral Treatment For Patients With Nonsegmental Vitiligo	CI

4b7a77080a.KYIzB3Pq8wvXWYjGJ4y6zK_fyXiyVc2l6oxc64Vfv3M.eM9WbiPao0KdHrq0YbyXi5mw8DrkPIHUp-kPsbUw8D5E6XBwSqOec5sg7w~0caf07409dc3ed2a6efd77d2bf0267f2

Analysts' recommendations: Pfizer

10-02	Pfizer Tilrekimig Data Support TSLP Role in Atopic Dermatitis, UBS Says	MT
10-02	Jefferies Adjusts Price Target on Pfizer to $35 From $34, Keeps Buy Rating	MT
10-02	Pfizer Inc. : Jefferies maintains a Buy rating	ZD
10-02	Pfizer Inc. : UBS is Neutral	ZD
09-24	Pfizer Inc. : JP Morgan is Neutral	ZD
09-09	BMO Capital Adjusts Price Target on Pfizer to $35 From $30, Keeps Outperform Rating	MT
08-18	Pfizer Pick of the Week at Smart Insider Following CEO's First Share Purchase	MT
08-12	Daiwa Securities Adjusts Price Target on Pfizer to $27 From $28, Maintains Neutral Rating	MT
08-07	Bernstein Adjusts Price Target on Pfizer to $29 From $30, Maintains Market Perform Rating	MT
08-07	Guggenheim Adjusts Price Target on Pfizer to $31 From $35, Maintains Buy Rating	MT
08-06	Pfizer Still in the Green, Goldman Sachs Neutral
08-06	PFIZER INC : DZ Bank reiterates its Buy rating	ZD
08-05	Rothschild & Co Redburn Adjusts Pfizer Price Target to $25 From $24, Maintains Neutral Rating	MT
08-05	PFIZER INC : Berenberg remains Neutral	ZD
08-05	PFIZER INC : Jefferies gives a Buy rating	ZD
08-04	PFIZER INC : JP Morgan remains Neutral	ZD
08-04	Wall Street Bets on the Magnificent Seven Again
07-30	PFIZER INC : RBC reiterates its Neutral rating	ZD
07-13	BMO Capital Adjusts Price Target on Pfizer to $30 From $34, Maintains Outperform Rating	MT
07-10	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says	MT
07-10	Pfizer Poised for Mixed Second Quarter, RBC Says	MT
07-10	BofA Securities Adjusts Pfizer Price Target to $26 From $27	MT
07-10	PFIZER INC : RBC reiterates its Neutral rating	ZD
07-08	Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says	MT
07-08	JPMorgan Adjusts Price Target on Pfizer to $28 From $30	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+16.27%
	JOHNSON & JOHNSON					+9.08%
	ABBVIE INC.					+6.1%
	MERCK & CO., INC.					+7.94%
	ROCHE HOLDING AG					+8.57%
	NOVARTIS AG					+8.14%
	ASTRAZENECA PLC					+34.02%
	AMGEN INC.					-3%
	GILEAD SCIENCES, INC.					+9.61%
	Average					+10.75%
	Weighted average by Cap.					+11.42%